http://142-54-23-223.fusionmedialtd.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 08 Jul 2026 07:01:16 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://142-54-23-223.fusionmedialtd.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html <p>Aura Biosciences, Inc. (NASDAQ: AURA) has appointed Jeremy Bender, Ph.D., M.B.A., to its board of directors, the clinical-stage biotechnology company announced.</p> <p>Bender most recently served as chief executive officer, president and board member of Day One Biopharmaceuticals, where he led the company through the approval and launch of OJEMDA® for pediatric low-grade glioma and its approximately $2.5 billion acquisition by Servier in 2026.</p> <p>Prior to Day One, Bender served as vice president of corporate development at Gilead Sciences. Earlier in his career, he held executive roles at Tizona Therapeutics, Sutro Biopharma and Allos Therapeutics, and began his career in the life sciences http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html Wed, 08 Jul 2026 07:01:16 -0400 0A9G A.01270702 A.11608963 A.13459824 A.24244367 A.41769919 A.50114148 A.50114187 A.60005112 A.60012009 AURA MREO O.00092932 O.05010326 O.07116383 O.22047037 O.22553658 O.30001160 O.34387572 O.34911615 O.37621794 O.50600732 http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html <p>Aura Biosciences, Inc. (NASDAQ: AURA) has appointed Jeremy Bender, Ph.D., M.B.A., to its board of directors, the clinical-stage biotechnology company announced.</p> <p>Bender most recently served as chief executive officer, president and board member of Day One Biopharmaceuticals, where he led the company through the approval and launch of OJEMDA® for pediatric low-grade glioma and its approximately $2.5 billion acquisition by Servier in 2026.</p> <p>Prior to Day One, Bender served as vice president of corporate development at Gilead Sciences. Earlier in his career, he held executive roles at Tizona Therapeutics, Sutro Biopharma and Allos Therapeutics, and began his career in the life sciences http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html Wed, 08 Jul 2026 07:01:16 -0400 0A9G A.01270702 A.11608963 A.13459824 A.24244367 A.41769919 A.50114148 A.50114187 A.60005112 A.60012009 AURA MREO O.00092932 O.05010326 O.07116383 O.22047037 O.22553658 O.30001160 O.34387572 O.34911615 O.37621794 O.50600732 http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html <p>Aura Biosciences, Inc. (NASDAQ: AURA) has appointed Jeremy Bender, Ph.D., M.B.A., to its board of directors, the clinical-stage biotechnology company announced.</p> <p>Bender most recently served as chief executive officer, president and board member of Day One Biopharmaceuticals, where he led the company through the approval and launch of OJEMDA® for pediatric low-grade glioma and its approximately $2.5 billion acquisition by Servier in 2026.</p> <p>Prior to Day One, Bender served as vice president of corporate development at Gilead Sciences. Earlier in his career, he held executive roles at Tizona Therapeutics, Sutro Biopharma and Allos Therapeutics, and began his career in the life sciences http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html Wed, 08 Jul 2026 07:01:16 -0400 0A9G A.01270702 A.11608963 A.13459824 A.24244367 A.41769919 A.50114148 A.50114187 A.60005112 A.60012009 AURA MREO O.00092932 O.05010326 O.07116383 O.22047037 O.22553658 O.30001160 O.34387572 O.34911615 O.37621794 O.50600732 http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html <p>Aura Biosciences, Inc. (NASDAQ: AURA) has appointed Jeremy Bender, Ph.D., M.B.A., to its board of directors, the clinical-stage biotechnology company announced.</p> <p>Bender most recently served as chief executive officer, president and board member of Day One Biopharmaceuticals, where he led the company through the approval and launch of OJEMDA® for pediatric low-grade glioma and its approximately $2.5 billion acquisition by Servier in 2026.</p> <p>Prior to Day One, Bender served as vice president of corporate development at Gilead Sciences. Earlier in his career, he held executive roles at Tizona Therapeutics, Sutro Biopharma and Allos Therapeutics, and began his career in the life sciences http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html Wed, 08 Jul 2026 07:01:16 -0400 0A9G A.01270702 A.11608963 A.13459824 A.24244367 A.41769919 A.50114148 A.50114187 A.60005112 A.60012009 AURA MREO O.00092932 O.05010326 O.07116383 O.22047037 O.22553658 O.30001160 O.34387572 O.34911615 O.37621794 O.50600732 http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html <p>Aura Biosciences, Inc. (NASDAQ: AURA) has appointed Jeremy Bender, Ph.D., M.B.A., to its board of directors, the clinical-stage biotechnology company announced.</p> <p>Bender most recently served as chief executive officer, president and board member of Day One Biopharmaceuticals, where he led the company through the approval and launch of OJEMDA® for pediatric low-grade glioma and its approximately $2.5 billion acquisition by Servier in 2026.</p> <p>Prior to Day One, Bender served as vice president of corporate development at Gilead Sciences. Earlier in his career, he held executive roles at Tizona Therapeutics, Sutro Biopharma and Allos Therapeutics, and began his career in the life sciences http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html Wed, 08 Jul 2026 07:01:16 -0400 0A9G A.01270702 A.11608963 A.13459824 A.24244367 A.41769919 A.50114148 A.50114187 A.60005112 A.60012009 AURA MREO O.00092932 O.05010326 O.07116383 O.22047037 O.22553658 O.30001160 O.34387572 O.34911615 O.37621794 O.50600732 http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html <p>Aura Biosciences, Inc. (NASDAQ: AURA) has appointed Jeremy Bender, Ph.D., M.B.A., to its board of directors, the clinical-stage biotechnology company announced.</p> <p>Bender most recently served as chief executive officer, president and board member of Day One Biopharmaceuticals, where he led the company through the approval and launch of OJEMDA® for pediatric low-grade glioma and its approximately $2.5 billion acquisition by Servier in 2026.</p> <p>Prior to Day One, Bender served as vice president of corporate development at Gilead Sciences. Earlier in his career, he held executive roles at Tizona Therapeutics, Sutro Biopharma and Allos Therapeutics, and began his career in the life sciences http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html Wed, 08 Jul 2026 07:01:16 -0400 0A9G A.01270702 A.11608963 A.13459824 A.24244367 A.41769919 A.50114148 A.50114187 A.60005112 A.60012009 AURA MREO O.00092932 O.05010326 O.07116383 O.22047037 O.22553658 O.30001160 O.34387572 O.34911615 O.37621794 O.50600732 http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html <p>Aura Biosciences, Inc. (NASDAQ: AURA) has appointed Jeremy Bender, Ph.D., M.B.A., to its board of directors, the clinical-stage biotechnology company announced.</p> <p>Bender most recently served as chief executive officer, president and board member of Day One Biopharmaceuticals, where he led the company through the approval and launch of OJEMDA® for pediatric low-grade glioma and its approximately $2.5 billion acquisition by Servier in 2026.</p> <p>Prior to Day One, Bender served as vice president of corporate development at Gilead Sciences. Earlier in his career, he held executive roles at Tizona Therapeutics, Sutro Biopharma and Allos Therapeutics, and began his career in the life sciences http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html Wed, 08 Jul 2026 07:01:16 -0400 0A9G A.01270702 A.11608963 A.13459824 A.24244367 A.41769919 A.50114148 A.50114187 A.60005112 A.60012009 AURA MREO O.00092932 O.05010326 O.07116383 O.22047037 O.22553658 O.30001160 O.34387572 O.34911615 O.37621794 O.50600732 http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html <p>Aura Biosciences, Inc. (NASDAQ: AURA) has appointed Jeremy Bender, Ph.D., M.B.A., to its board of directors, the clinical-stage biotechnology company announced.</p> <p>Bender most recently served as chief executive officer, president and board member of Day One Biopharmaceuticals, where he led the company through the approval and launch of OJEMDA® for pediatric low-grade glioma and its approximately $2.5 billion acquisition by Servier in 2026.</p> <p>Prior to Day One, Bender served as vice president of corporate development at Gilead Sciences. Earlier in his career, he held executive roles at Tizona Therapeutics, Sutro Biopharma and Allos Therapeutics, and began his career in the life sciences http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html Wed, 08 Jul 2026 07:01:16 -0400 0A9G A.01270702 A.11608963 A.13459824 A.24244367 A.41769919 A.50114148 A.50114187 A.60005112 A.60012009 AURA MREO O.00092932 O.05010326 O.07116383 O.22047037 O.22553658 O.30001160 O.34387572 O.34911615 O.37621794 O.50600732 http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html <p>Aura Biosciences, Inc. (NASDAQ: AURA) has appointed Jeremy Bender, Ph.D., M.B.A., to its board of directors, the clinical-stage biotechnology company announced.</p> <p>Bender most recently served as chief executive officer, president and board member of Day One Biopharmaceuticals, where he led the company through the approval and launch of OJEMDA® for pediatric low-grade glioma and its approximately $2.5 billion acquisition by Servier in 2026.</p> <p>Prior to Day One, Bender served as vice president of corporate development at Gilead Sciences. Earlier in his career, he held executive roles at Tizona Therapeutics, Sutro Biopharma and Allos Therapeutics, and began his career in the life sciences http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html Wed, 08 Jul 2026 07:01:16 -0400 0A9G A.01270702 A.11608963 A.13459824 A.24244367 A.41769919 A.50114148 A.50114187 A.60005112 A.60012009 AURA MREO O.00092932 O.05010326 O.07116383 O.22047037 O.22553658 O.30001160 O.34387572 O.34911615 O.37621794 O.50600732 http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html <p>Aura Biosciences, Inc. (NASDAQ: AURA) has appointed Jeremy Bender, Ph.D., M.B.A., to its board of directors, the clinical-stage biotechnology company announced.</p> <p>Bender most recently served as chief executive officer, president and board member of Day One Biopharmaceuticals, where he led the company through the approval and launch of OJEMDA® for pediatric low-grade glioma and its approximately $2.5 billion acquisition by Servier in 2026.</p> <p>Prior to Day One, Bender served as vice president of corporate development at Gilead Sciences. Earlier in his career, he held executive roles at Tizona Therapeutics, Sutro Biopharma and Allos Therapeutics, and began his career in the life sciences http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html Wed, 08 Jul 2026 07:01:16 -0400 0A9G A.01270702 A.11608963 A.13459824 A.24244367 A.41769919 A.50114148 A.50114187 A.60005112 A.60012009 AURA MREO O.00092932 O.05010326 O.07116383 O.22047037 O.22553658 O.30001160 O.34387572 O.34911615 O.37621794 O.50600732 http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html <p>Aura Biosciences, Inc. (NASDAQ: AURA) has appointed Jeremy Bender, Ph.D., M.B.A., to its board of directors, the clinical-stage biotechnology company announced.</p> <p>Bender most recently served as chief executive officer, president and board member of Day One Biopharmaceuticals, where he led the company through the approval and launch of OJEMDA® for pediatric low-grade glioma and its approximately $2.5 billion acquisition by Servier in 2026.</p> <p>Prior to Day One, Bender served as vice president of corporate development at Gilead Sciences. Earlier in his career, he held executive roles at Tizona Therapeutics, Sutro Biopharma and Allos Therapeutics, and began his career in the life sciences http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html Wed, 08 Jul 2026 07:01:16 -0400 0A9G A.01270702 A.11608963 A.13459824 A.24244367 A.41769919 A.50114148 A.50114187 A.60005112 A.60012009 AURA MREO O.00092932 O.05010326 O.07116383 O.22047037 O.22553658 O.30001160 O.34387572 O.34911615 O.37621794 O.50600732 http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html <p>Aura Biosciences, Inc. (NASDAQ: AURA) has appointed Jeremy Bender, Ph.D., M.B.A., to its board of directors, the clinical-stage biotechnology company announced.</p> <p>Bender most recently served as chief executive officer, president and board member of Day One Biopharmaceuticals, where he led the company through the approval and launch of OJEMDA® for pediatric low-grade glioma and its approximately $2.5 billion acquisition by Servier in 2026.</p> <p>Prior to Day One, Bender served as vice president of corporate development at Gilead Sciences. Earlier in his career, he held executive roles at Tizona Therapeutics, Sutro Biopharma and Allos Therapeutics, and began his career in the life sciences http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html Wed, 08 Jul 2026 07:01:16 -0400 0A9G A.01270702 A.11608963 A.13459824 A.24244367 A.41769919 A.50114148 A.50114187 A.60005112 A.60012009 AURA MREO O.00092932 O.05010326 O.07116383 O.22047037 O.22553658 O.30001160 O.34387572 O.34911615 O.37621794 O.50600732 http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html <p>Aura Biosciences, Inc. (NASDAQ: AURA) has appointed Jeremy Bender, Ph.D., M.B.A., to its board of directors, the clinical-stage biotechnology company announced.</p> <p>Bender most recently served as chief executive officer, president and board member of Day One Biopharmaceuticals, where he led the company through the approval and launch of OJEMDA® for pediatric low-grade glioma and its approximately $2.5 billion acquisition by Servier in 2026.</p> <p>Prior to Day One, Bender served as vice president of corporate development at Gilead Sciences. Earlier in his career, he held executive roles at Tizona Therapeutics, Sutro Biopharma and Allos Therapeutics, and began his career in the life sciences http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html Wed, 08 Jul 2026 07:01:16 -0400 0A9G A.01270702 A.11608963 A.13459824 A.24244367 A.41769919 A.50114148 A.50114187 A.60005112 A.60012009 AURA MREO O.00092932 O.05010326 O.07116383 O.22047037 O.22553658 O.30001160 O.34387572 O.34911615 O.37621794 O.50600732 http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html <p>Aura Biosciences, Inc. (NASDAQ: AURA) has appointed Jeremy Bender, Ph.D., M.B.A., to its board of directors, the clinical-stage biotechnology company announced.</p> <p>Bender most recently served as chief executive officer, president and board member of Day One Biopharmaceuticals, where he led the company through the approval and launch of OJEMDA® for pediatric low-grade glioma and its approximately $2.5 billion acquisition by Servier in 2026.</p> <p>Prior to Day One, Bender served as vice president of corporate development at Gilead Sciences. Earlier in his career, he held executive roles at Tizona Therapeutics, Sutro Biopharma and Allos Therapeutics, and began his career in the life sciences http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html Wed, 08 Jul 2026 07:01:16 -0400 0A9G A.01270702 A.11608963 A.13459824 A.24244367 A.41769919 A.50114148 A.50114187 A.60005112 A.60012009 AURA MREO O.00092932 O.05010326 O.07116383 O.22047037 O.22553658 O.30001160 O.34387572 O.34911615 O.37621794 O.50600732 http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html <p>Aura Biosciences, Inc. (NASDAQ: AURA) has appointed Jeremy Bender, Ph.D., M.B.A., to its board of directors, the clinical-stage biotechnology company announced.</p> <p>Bender most recently served as chief executive officer, president and board member of Day One Biopharmaceuticals, where he led the company through the approval and launch of OJEMDA® for pediatric low-grade glioma and its approximately $2.5 billion acquisition by Servier in 2026.</p> <p>Prior to Day One, Bender served as vice president of corporate development at Gilead Sciences. Earlier in his career, he held executive roles at Tizona Therapeutics, Sutro Biopharma and Allos Therapeutics, and began his career in the life sciences http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html Wed, 08 Jul 2026 07:01:16 -0400 0A9G A.01270702 A.11608963 A.13459824 A.24244367 A.41769919 A.50114148 A.50114187 A.60005112 A.60012009 AURA MREO O.00092932 O.05010326 O.07116383 O.22047037 O.22553658 O.30001160 O.34387572 O.34911615 O.37621794 O.50600732 http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html <p>Aura Biosciences, Inc. (NASDAQ: AURA) has appointed Jeremy Bender, Ph.D., M.B.A., to its board of directors, the clinical-stage biotechnology company announced.</p> <p>Bender most recently served as chief executive officer, president and board member of Day One Biopharmaceuticals, where he led the company through the approval and launch of OJEMDA® for pediatric low-grade glioma and its approximately $2.5 billion acquisition by Servier in 2026.</p> <p>Prior to Day One, Bender served as vice president of corporate development at Gilead Sciences. Earlier in his career, he held executive roles at Tizona Therapeutics, Sutro Biopharma and Allos Therapeutics, and began his career in the life sciences http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html Wed, 08 Jul 2026 07:01:16 -0400 0A9G A.01270702 A.11608963 A.13459824 A.24244367 A.41769919 A.50114148 A.50114187 A.60005112 A.60012009 AURA MREO O.00092932 O.05010326 O.07116383 O.22047037 O.22553658 O.30001160 O.34387572 O.34911615 O.37621794 O.50600732 http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html <p>Aura Biosciences, Inc. (NASDAQ: AURA) has appointed Jeremy Bender, Ph.D., M.B.A., to its board of directors, the clinical-stage biotechnology company announced.</p> <p>Bender most recently served as chief executive officer, president and board member of Day One Biopharmaceuticals, where he led the company through the approval and launch of OJEMDA® for pediatric low-grade glioma and its approximately $2.5 billion acquisition by Servier in 2026.</p> <p>Prior to Day One, Bender served as vice president of corporate development at Gilead Sciences. Earlier in his career, he held executive roles at Tizona Therapeutics, Sutro Biopharma and Allos Therapeutics, and began his career in the life sciences http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html Wed, 08 Jul 2026 07:01:16 -0400 0A9G A.01270702 A.11608963 A.13459824 A.24244367 A.41769919 A.50114148 A.50114187 A.60005112 A.60012009 AURA MREO O.00092932 O.05010326 O.07116383 O.22047037 O.22553658 O.30001160 O.34387572 O.34911615 O.37621794 O.50600732 http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html <p>Aura Biosciences, Inc. (NASDAQ: AURA) has appointed Jeremy Bender, Ph.D., M.B.A., to its board of directors, the clinical-stage biotechnology company announced.</p> <p>Bender most recently served as chief executive officer, president and board member of Day One Biopharmaceuticals, where he led the company through the approval and launch of OJEMDA® for pediatric low-grade glioma and its approximately $2.5 billion acquisition by Servier in 2026.</p> <p>Prior to Day One, Bender served as vice president of corporate development at Gilead Sciences. Earlier in his career, he held executive roles at Tizona Therapeutics, Sutro Biopharma and Allos Therapeutics, and began his career in the life sciences http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html Wed, 08 Jul 2026 07:01:16 -0400 0A9G A.01270702 A.11608963 A.13459824 A.24244367 A.41769919 A.50114148 A.50114187 A.60005112 A.60012009 AURA MREO O.00092932 O.05010326 O.07116383 O.22047037 O.22553658 O.30001160 O.34387572 O.34911615 O.37621794 O.50600732 http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html <p>Aura Biosciences, Inc. (NASDAQ: AURA) has appointed Jeremy Bender, Ph.D., M.B.A., to its board of directors, the clinical-stage biotechnology company announced.</p> <p>Bender most recently served as chief executive officer, president and board member of Day One Biopharmaceuticals, where he led the company through the approval and launch of OJEMDA® for pediatric low-grade glioma and its approximately $2.5 billion acquisition by Servier in 2026.</p> <p>Prior to Day One, Bender served as vice president of corporate development at Gilead Sciences. Earlier in his career, he held executive roles at Tizona Therapeutics, Sutro Biopharma and Allos Therapeutics, and began his career in the life sciences http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html Wed, 08 Jul 2026 07:01:16 -0400 0A9G A.01270702 A.11608963 A.13459824 A.24244367 A.41769919 A.50114148 A.50114187 A.60005112 A.60012009 AURA MREO O.00092932 O.05010326 O.07116383 O.22047037 O.22553658 O.30001160 O.34387572 O.34911615 O.37621794 O.50600732 http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html <p>Aura Biosciences, Inc. (NASDAQ: AURA) has appointed Jeremy Bender, Ph.D., M.B.A., to its board of directors, the clinical-stage biotechnology company announced.</p> <p>Bender most recently served as chief executive officer, president and board member of Day One Biopharmaceuticals, where he led the company through the approval and launch of OJEMDA® for pediatric low-grade glioma and its approximately $2.5 billion acquisition by Servier in 2026.</p> <p>Prior to Day One, Bender served as vice president of corporate development at Gilead Sciences. Earlier in his career, he held executive roles at Tizona Therapeutics, Sutro Biopharma and Allos Therapeutics, and began his career in the life sciences http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html Wed, 08 Jul 2026 07:01:16 -0400 0A9G A.01270702 A.11608963 A.13459824 A.24244367 A.41769919 A.50114148 A.50114187 A.60005112 A.60012009 AURA MREO O.00092932 O.05010326 O.07116383 O.22047037 O.22553658 O.30001160 O.34387572 O.34911615 O.37621794 O.50600732 http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html <p>Aura Biosciences, Inc. (NASDAQ: AURA) has appointed Jeremy Bender, Ph.D., M.B.A., to its board of directors, the clinical-stage biotechnology company announced.</p> <p>Bender most recently served as chief executive officer, president and board member of Day One Biopharmaceuticals, where he led the company through the approval and launch of OJEMDA® for pediatric low-grade glioma and its approximately $2.5 billion acquisition by Servier in 2026.</p> <p>Prior to Day One, Bender served as vice president of corporate development at Gilead Sciences. Earlier in his career, he held executive roles at Tizona Therapeutics, Sutro Biopharma and Allos Therapeutics, and began his career in the life sciences http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html Wed, 08 Jul 2026 07:01:16 -0400 0A9G A.01270702 A.11608963 A.13459824 A.24244367 A.41769919 A.50114148 A.50114187 A.60005112 A.60012009 AURA MREO O.00092932 O.05010326 O.07116383 O.22047037 O.22553658 O.30001160 O.34387572 O.34911615 O.37621794 O.50600732 http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html <p>Aura Biosciences, Inc. (NASDAQ: AURA) has appointed Jeremy Bender, Ph.D., M.B.A., to its board of directors, the clinical-stage biotechnology company announced.</p> <p>Bender most recently served as chief executive officer, president and board member of Day One Biopharmaceuticals, where he led the company through the approval and launch of OJEMDA® for pediatric low-grade glioma and its approximately $2.5 billion acquisition by Servier in 2026.</p> <p>Prior to Day One, Bender served as vice president of corporate development at Gilead Sciences. Earlier in his career, he held executive roles at Tizona Therapeutics, Sutro Biopharma and Allos Therapeutics, and began his career in the life sciences http://www.streetinsider.com/Board+Changes/Aura+Biosciences+adds+former+Day+One+CEO+to+its+board/26744137.html Wed, 08 Jul 2026 07:01:16 -0400 0A9G A.01270702 A.11608963 A.13459824 A.24244367 A.41769919 A.50114148 A.50114187 A.60005112 A.60012009 AURA MREO O.00092932 O.05010326 O.07116383 O.22047037 O.22553658 O.30001160 O.34387572 O.34911615 O.37621794 O.50600732 http://www.streetinsider.com/Press+Releases/Aura+Biosciences+Announces+Appointment+of+Jeremy+Bender%2C+Ph.D.%2C+M.B.A.%2C+to+Board+of+Directors/26744133.html <p align="justify">BOSTON, July 08, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=8b0MCqn2fmRZWdbwn4j2QufQaCYC3WSP4voMop-Izf8e4GhZUZ7z-7Sa-fleDX3W4PQy19N66AbevrSCoB_GCBdbkvx3sOXQK4qifQgMtTlnsO7cCbp6JKThg69wO0OM" rel="nofollow" target="_blank">Aura Biosciences, Inc.</a> (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Jeremy Bender, Ph.D., M.B.A., to its Board of Directors.</p> <p align="justify">“I am thrilled to welcome Jeremy to our Board of Directors and excited to be working alongside him again,” said Natalie Holles, Chief Executive Officer of Aura Biosciences. “Jeremy is an accomplished biotechnology leader with deep experience advancing innovative therapies through late-stage development, commercialization and significant value creation in rare http://www.streetinsider.com/Press+Releases/Aura+Biosciences+Announces+Appointment+of+Jeremy+Bender%2C+Ph.D.%2C+M.B.A.%2C+to+Board+of+Directors/26744133.html Wed, 08 Jul 2026 07:01:00 -0400 0A9G A.01270702 A.11608963 A.13459824 A.24244367 A.41769919 A.50114148 A.50114187 A.60005112 A.60012009 AURA MREO O.00092932 O.05010326 O.07116383 O.22047037 O.22553658 O.30001160 O.34387572 O.34911615 O.37621794 O.50600732 http://www.streetinsider.com/Press+Releases/Aura+Biosciences+Announces+Appointment+of+Jeremy+Bender%2C+Ph.D.%2C+M.B.A.%2C+to+Board+of+Directors/26744133.html <p align="justify">BOSTON, July 08, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=8b0MCqn2fmRZWdbwn4j2QufQaCYC3WSP4voMop-Izf8e4GhZUZ7z-7Sa-fleDX3W4PQy19N66AbevrSCoB_GCBdbkvx3sOXQK4qifQgMtTlnsO7cCbp6JKThg69wO0OM" rel="nofollow" target="_blank">Aura Biosciences, Inc.</a> (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Jeremy Bender, Ph.D., M.B.A., to its Board of Directors.</p> <p align="justify">“I am thrilled to welcome Jeremy to our Board of Directors and excited to be working alongside him again,” said Natalie Holles, Chief Executive Officer of Aura Biosciences. “Jeremy is an accomplished biotechnology leader with deep experience advancing innovative therapies through late-stage development, commercialization and significant value creation in rare http://www.streetinsider.com/Press+Releases/Aura+Biosciences+Announces+Appointment+of+Jeremy+Bender%2C+Ph.D.%2C+M.B.A.%2C+to+Board+of+Directors/26744133.html Wed, 08 Jul 2026 07:01:00 -0400 0A9G A.01270702 A.11608963 A.13459824 A.24244367 A.41769919 A.50114148 A.50114187 A.60005112 A.60012009 AURA MREO O.00092932 O.05010326 O.07116383 O.22047037 O.22553658 O.30001160 O.34387572 O.34911615 O.37621794 O.50600732 http://www.streetinsider.com/Press+Releases/Aura+Biosciences+Announces+Appointment+of+Jeremy+Bender%2C+Ph.D.%2C+M.B.A.%2C+to+Board+of+Directors/26744133.html <p align="justify">BOSTON, July 08, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=8b0MCqn2fmRZWdbwn4j2QufQaCYC3WSP4voMop-Izf8e4GhZUZ7z-7Sa-fleDX3W4PQy19N66AbevrSCoB_GCBdbkvx3sOXQK4qifQgMtTlnsO7cCbp6JKThg69wO0OM" rel="nofollow" target="_blank">Aura Biosciences, Inc.</a> (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Jeremy Bender, Ph.D., M.B.A., to its Board of Directors.</p> <p align="justify">“I am thrilled to welcome Jeremy to our Board of Directors and excited to be working alongside him again,” said Natalie Holles, Chief Executive Officer of Aura Biosciences. “Jeremy is an accomplished biotechnology leader with deep experience advancing innovative therapies through late-stage development, commercialization and significant value creation in rare http://www.streetinsider.com/Press+Releases/Aura+Biosciences+Announces+Appointment+of+Jeremy+Bender%2C+Ph.D.%2C+M.B.A.%2C+to+Board+of+Directors/26744133.html Wed, 08 Jul 2026 07:01:00 -0400 0A9G A.01270702 A.11608963 A.13459824 A.24244367 A.41769919 A.50114148 A.50114187 A.60005112 A.60012009 AURA MREO O.00092932 O.05010326 O.07116383 O.22047037 O.22553658 O.30001160 O.34387572 O.34911615 O.37621794 O.50600732